Results 91 to 100 of about 18,326 (214)

Indolent zygomycosis associated with deferoxamine chelation therapy [PDF]

open access: yes, 1994
This paper describes a 71-year-old man with myelodysplasia who required multiple transfusions and subsequent deferoxamine chelation therapy and who then developed indolent cutaneous and probable pulmonary infection with Rhizopus species.
Bradley, Suzanne F.   +5 more
core   +1 more source

Deferoxamine-Loaded Chitosan-Based Hydrogel on Bone Implants Showing Enhanced Bond Strength and Pro-Angiogenic Effects

open access: yesJournal of Functional Biomaterials
Angiogenesis is vital for bone fracture healing and plays a significant role in the fate of orthopedic implants. The growth and maintenance of new blood vessels at the fracture site of patients is essential, which promotes the clinical outcome of plasma ...
Huan Liu   +5 more
doaj   +1 more source

Deferoxamine in thalassemia major.

open access: yes, 1995
Comment on: Survival in medically treated patients with homozygous beta-thalassemia. [N Engl J Med. 1994] Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
CAZZOLA, MARIO   +2 more
core  

How early can myocardial iron overload occur in Beta thalassemia major? [PDF]

open access: yes, 2014
BACKGROUND: Myocardial siderosis is the most common cause of death in patients with beta thalassemia major(TM). This study aimed at investigating the occurrence, prevalence and severity of cardiac iron overload in a young Chinese population with beta TM.
Gaohui Yang   +34 more
core   +2 more sources

ICOS‐ImmunoPET Monitors T Cell Activation After Combination Immune Checkpoint Blockade in a Mouse Model of Melanoma Brain Metastasis

open access: yesAdvanced Science, Volume 13, Issue 56, 9 October 2026.
ICOS‐immunoPET noninvasively visualizes activated T cells in melanoma brain metastases following combined anti‐PD‐1/anti‐CTLA‐4 therapy. Clinical translation of this imaging approach may improve patient stratification and treatment monitoring and serve as a quantitative imaging endpoint to support immunotherapy development and clinical trials in brain ...
Renesmee C. Kuo   +10 more
wiley   +1 more source

Coronary venous retroinfusion of deferoxamine reduces infarct size in pigs [PDF]

open access: yes, 1991
The efficacy of coronary venous retroinfusion of the iron chelator deferoxamine was studied in 24 pentobarbital-anesthetized open chest pigs with a 60 min occlusion of the left anterior descending coronary artery followed by 3 h of reperfusion.
Nordlander, Rolf   +6 more
core   +1 more source

Anemia From Inflammation After Intracerebral Hemorrhage and Relationships With Outcome

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Baseline anemia is associated with poor intracerebral hemorrhage (ICH) outcomes. However, underlying drivers for anemia and whether anemia development after ICH impacts clinical outcomes are unknown.
David J. Roh   +19 more
doaj   +1 more source

Iron and Other Metal Ions in Human Health and Disease

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Iron, copper, zinc, and calcium orchestrate cellular function through distinct yet cooperative mechanisms: redox‐active iron and copper cycle between oxidation states to act as Fenton catalysts and electron carriers in oxidative phosphorylation (OXPHOS); redox‐inert zinc serves as a structural component of zinc‐finger proteins and a catalytic cofactor ...
Xiaofeng Dai, Jitian Li
wiley   +1 more source

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload

open access: yes, 2018
Dijiong Wu,1 Xiaowen Wen,2 Wenbin Liu,1 Huijin Hu,1 Baodong Ye,1 Yuhong Zhou1 1Department of Hematology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China; 2Department of Internal ...
Wen X, Hu H, Ye B, Wu D, Zhou Y, Liu W
core  

PROTECTIVE EFFECT OF THE IRON CHELATOR DEFEROXAMINE ON CEREBRAL VASOSPASM

open access: yes, 1992
Experimental studies suggest the primary role of free radical products in the development of vasospasm. In the present study, the iron chelator deferoxamine was used at the time of subarachnoid hemorrhage to prevent chronic cerebral vasospasm.
KILINC, K   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy